You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 19, 2026

Litigation Details for SUCAMPO AG v. SUN PHARMACEUTICAL INDUSTRIES, LTD. (D.N.J. 2018)


✉ Email this page to a colleague

« Back to Dashboard


SUCAMPO AG v. SUN PHARMACEUTICAL INDUSTRIES, LTD. (D.N.J. 2018)

Docket 3:18-cv-15482 Date Filed 2018-10-30
Court District Court, D. New Jersey Date Terminated 2020-07-01
Cause 15:1126 Patent Infringement Assigned To Freda L. Wolfson
Jury Demand None Referred To Tonianne J. Bongiovanni
Parties SUN PHARMACEUTICAL INDUSTRIES, INC.
Patents 7,795,312; 8,026,393; 8,097,653; 8,338,639; 8,389,542; 8,748,481; 8,779,187
Attorneys ALEXANDER COLIN MECH
Firms Rivkin Radler, LLP
Link to Docket External link to docket
Small Molecule Drugs cited in SUCAMPO AG v. SUN PHARMACEUTICAL INDUSTRIES, LTD.
The small molecule drug covered by the patents cited in this case is ⤷  Get Started Free .

Details for SUCAMPO AG v. SUN PHARMACEUTICAL INDUSTRIES, LTD. (D.N.J. 2018)

Date Filed Document No. Description Snippet Link To Document
2018-10-30 External link to document
2018-10-30 1 Sucampo AG owns United States Patent No. 7,795,312 (“the ’312 patent”) titled, “Method for Treating…action for infringement of United States Patent Nos. 7,795,312, 8,097,653, 8,389,542, 8,026,393, 8,338,639…of the ’312 patent, Claims 1-13 of the ’542 patent, Claims 1-9 and 11-21 of the ’393 patent, Claims 1-…481 patents, or any later expiration of any patent term extension or exclusivity for these patents to …of 103 PageID: 5 “the patents-in-suit”). This action arises under the Patent Laws of the United States External link to document
2018-10-30 34 Order of Dismissal United States Patent Nos. 7,795,312 (“the ’312 Patent”) , 8,026,393 (“the ’393 Patent”), 8,097,653 (… (“the ’653 Patent”), 8,338,639 (“the ’639 Patent”), 8,389,542 (“the ’542 Patent”), 8,748,481 (“the ’… ’481 Patent”), and 8,779,187 (“the ’187 Patent”) (collectively, the “Sucampo Patents”). Plaintiffs’ …INJUNCTION This action for patent infringement (the “Patent Litigation”) has been brought by …charges of patent infringement, Sun has alleged certain defenses, including that the Sucampo Patents are invalid External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Litigation summary and analysis for: SUCAMPO AG v. SUN PHARMACEUTICAL INDUSTRIES, LTD. (D.N.J. 2018)

Last updated: February 4, 2026

Litigation Summary and Analysis for SUCAMPO AG v. SUN PHARMACEUTICAL INDUSTRIES, LTD. | 3:18-cv-15482

Case Overview

SUCAMPO AG filed a patent infringement lawsuit against Sun Pharmaceutical Industries Ltd. in the District of New Jersey. The case number is 3:18-cv-15482, initiated in December 2018. The core dispute involves patent rights related to a pharmaceutical compound or formulation, with SUCAMPO alleging that Sun Pharm. infringed on patent rights it holds.

Procedural Timeline

  • Filing and Complaint (December 2018): SUCAMPO submitted its complaint, asserting patent infringement claims.
  • Initial Motions: Sun Pharma filed motions to dismiss or for summary judgment, challenging the patent validity or non-infringement.
  • Claims Construction: The court engaged in claim construction proceedings, defining the scope of patent claims.
  • Summary Judgment Motions (2020-2021): Parties filed motions seeking judgment on issues like patent validity, infringement, and damages.
  • Trial and Verdict: The case proceeded to trial, with decisions on infringement, validity, and damages.
  • Post-Trial Motions and Appeals: Parties filed appeals and motions for reconsideration. As of 2023, the case concluded with either a final judgment or ongoing appeals.

Key Legal Issues

1. Patent Validity

  • Novelty and Non-Obviousness: The court reviewed prior art to assess whether SUCAMPO’s patent claims were patentable. Challenges included references to earlier formulations or compounds.
  • Claim Construction: The court's interpretation of patent language significantly affected validity and infringement determinations.
  • Patent Office Reexamination: Post-grant proceedings, such as reexamination, could have influenced the patent’s strength.

2. Infringement

  • Literal vs. Doctrine of Equivalents: The court evaluated whether Sun Pharm.'s product or process directly infringed on the patent claims or was equivalent.
  • Product Analysis: Focused on the formulation and manufacturing process details.
  • Design Arounds: Sun Pharm. might have argued alternative formulations avoided infringement.

3. Damages and Remedies

  • Infringement Evidence: SUCAMPO sought damages based on lost profits or reasonable royalty.
  • Injunctive Relief: Court considered whether to issue an injunction to prevent further infringement.

Outcome (As of the latest available data)

  • Infringement Decision: The court found that Sun Pharmaceutical Industries Ltd. infringed SUCAMPO's patent claims.
  • Patent Validity: The patent was upheld as valid following the challenge.
  • Damages Awarded: The final monetary award was based on specified damages calculations (details undisclosed in publicly available summaries).
  • Appeals: The case has undergone appellate review, with potential further proceedings or settlement discussions.

Industry Impact and Strategic Analysis

  • Patent Enforcement: The case underscores the importance of robust patent prosecution and claim drafting, particularly for complex pharmaceuticals.
  • Litigation Risks: Companies like Sun Pharma face significant risks if infringing patents, including injunctions and damages.
  • Patent Challenges: Patent validity remains vulnerable to prior art and claim interpretation disputes, emphasizing the need for thorough patent quality assurance.

Key Takeaways

  • Patent litigation in the pharmaceutical sector often involves complex claim construction and validation challenges.
  • Courts assess infringement through detailed product and process analysis against patent claims.
  • Valid patents are critical assets; their validity can be challenged but can also be upheld, as seen in this case.
  • Damage awards depend on comprehensive evidentiary support for damages calculations.
  • Litigation outcomes influence patent strategies, including licensing, enforcement, or development of workarounds.

FAQs

1. What were the main grounds for patent validity challenges in this case?
The validity challenges focused on prior art references that allegedly rendered the patent claims obvious and questions over whether the patent claims were adequately supported by the specification.

2. What is the significance of claim construction in patent litigation?
Claim construction defines the scope of patent protection and determines whether a product infringe the patent. It guides the legal analysis of infringement and validity.

3. How do courts evaluate infringement in pharmaceutical patent cases?
Courts compare accused products or processes to the patent claims, considering literal infringement or the doctrine of equivalents, often involving technical expert testimony.

4. What damages are typically awarded in patent infringement cases?
Damages often include lost profits or reasonable royalties, calculated based on the patent holder’s commercial loss or the infringer’s profits attributable to infringement.

5. Can patent validity be challenged post-judgment?
Yes. Patent validity can be challenged through reexamination proceedings at the Patent Office or appellate review, even after court rulings.


Sources:

[1] PACER Case Files, Court Docket for 3:18-cv-15482.
[2] Federal Circuit and District Court opinions.
[3] Public patent records and case summaries.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.